Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SIM1811-03 |
Synonyms | |
Therapy Description |
SIM1811-03 is a monoclonal antibody targeting TNFR2, which potentially induces antitumor activity (Annals of Oncology 34 (2023): S485). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SIM1811-03 | SIM1811 03|SIM181103|SIM0235|SIM-235|SIM 0235 | SIM1811-03 is a monoclonal antibody targeting TNFR2, which potentially induces antitumor activity (Annals of Oncology 34 (2023): S485). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05569057 | Phase I | SIM1811-03 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | Recruiting | USA | 0 |